Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

开始日期2025-02-10

申办/合作机构

Novo Nordisk A/S

NCT06797869

/ Recruiting临床2期

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

开始日期2025-01-29

申办/合作机构

Novo Nordisk A/S

NCT06716307

/ Recruiting临床1期

Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity

This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.

开始日期2024-12-02

申办/合作机构

Novo Nordisk A/S

100 项与 CagriSema 相关的临床结果

登录后查看更多信息

100 项与 CagriSema 相关的转化医学

登录后查看更多信息

100 项与 CagriSema 相关的专利（医药）

登录后查看更多信息

562

项与 CagriSema 相关的文献（医药）

2025-01-01·PHARMACOLOGICAL REVIEWS

Emerging pharmacotherapies for obesity: A systematic review

Review

作者: Al Rifai, Jana ; Valenzuela-Vallejo, Laura ; Rhayem, Caline ; Kokkorakis, Michail ; Mantzoros, Christos S ; Mantzoros, Christos S. ; Chakhtoura, Marlene ; Ghezzawi, Malak

The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024). We identified 53 phase 3 and phase 2 trials, with 36 emerging antiobesity drugs or combinations thereof and 4 withdrawn or terminated trials. Oral semaglutide 50 mg is the only medication that has completed a phase 3 trial. There are 14 ongoing phase 3 trials on glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (ecnoglutide, orforglipron, and TG103), GLP-1 RA/amylin agonist (CagriSema), GLP-1/glucagon RAs (mazdutide and survodutide), GLP-1/glucose-dependent insulinotropic polypeptide and glucagon RA (retatrutide), dapagliflozin, and the combination sibutramine/topiramate. Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%. Almost half of the drugs undergoing phase 2 trials are incretin analogs. The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs. Data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on underrepresented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity. SIGNIFICANCE STATEMENT: Obesity is the epidemic of the 21st century. Except for the newer injectable medications, drugs with suboptimal efficacy have been available in the clinician's armamentarium for weight management. However, emerging alternatives of novel agents and combinations populate the current obesity therapeutic pipeline. This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

2024-10-01·Current diabetes reviews

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity

Review

作者: Aliter, Hashem F. ; Al-Horani, Rami A. ; Aliter, Kholoud F.

Abstract::

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity

2024-09-01·Indian journal of endocrinology and metabolism

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

Review

作者: Sharma, Meha ; Joshi, Ameya ; Kamrul-Hasan, ABM ; Hathur, Basavanagowdappa ; Nagendra, Lakshmi ; Dutta, Deep ; Harish, BG

Abstract:

No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events. From 678 articles, data from 3 RCTs involving 430 individuals were analysed. At 20–32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)−9.07% (95%CI: −11.91, −6.23); P < 0.00001;I2 = 96%] and absolute [MD-9.11 kg (95%CI: −12.84, −5.39); P < 0.00001; I2 = 98%] weight-loss, compared to semaglutide 2.4 mg weekly. At 26–32 weeks, cagrilintide 2.4 mg had a similar percentage [MD − 1.83% (95%CI: −4.08, −0.42); P = 0.11; I2 = 98%] and absolute [MD − 1.88 kg (95%CI: −4.23,0.47); P = 0.12; I2 = 98%] weight-loss, compared to semaglutide/liraglutide. Treatment-emergent and serious adverse events were comparable between groups. Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide. Vomiting was significantly lower with cagrilintide compared to semaglutide/liraglutide. Cagrisema outperforms semaglutide regarding weight loss. Cagrilintide shows comparable weight loss to semaglutide/liraglutide with significantly lower vomiting.

233

项与 CagriSema 相关的新闻（医药）

2025-03-29

·抗体圈

诺和诺德再押 10 亿美元押注非 GLP-1 肥胖疗法：ACSL5 靶点成战略新支点

导语：2025 年 3 月，诺和诺德以最高 10 亿美元的交易金额与 Lexicon Pharmaceuticals 达成合作，获得后者非 GLP-1 肥胖候选药物 LX9851 的全球开发权。这款针对 ACSL5 酶的创新疗法，被视为诺和诺德在 GLP-1 领域遭遇增长瓶颈后，向代谢疾病治疗 “第二曲线” 的关键布局。一、交易细节：10 亿美元的 “战略对冲”支付结构：诺和诺德将支付 7500 万美元预付款及近期里程碑费用，未来根据研发、监管和销售进展支付最高 9.25 亿美元，此外还需支付分级销售分成。靶点创新：LX9851 通过抑制肝脏 ACSL5 酶，调节脂肪代谢并延缓胃排空，与 GLP-1 机制形成互补。临床前数据显示，其在小鼠模型中可显著减少食物摄入、体脂和体重，并改善肝脂肪变性。管线协同：诺和将负责后续临床试验及商业化，计划 2026 年启动 I 期研究，目标覆盖肥胖及相关代谢疾病。二、战略意义：GLP-1 帝国的 “未雨绸缪”突破专利悬崖：诺和 GLP-1 药物 Wegovy（减肥）和 Ozempic（糖尿病）2024 年销售额合计 200 亿美元，但专利保护将于 2030 年到期，急需新增长点。LX9851 的非 GLP-1 机制避开专利纠纷，且针对 GLP-1 耐药或不耐受患者，扩大市场覆盖。应对竞争压力：礼来的 tirzepatide（Zepbound）在 III 期试验中减重效果优于 Wegovy，迫使诺和加速差异化布局。诺和与中国联合实验室的合作（UBT251）、与 Lexicon 的交易，显示其 “多靶点、多机制” 的战略转向。三、技术突破：ACSL5 靶点的 “代谢革命”机制创新：ACSL5 酶参与脂肪酸代谢，抑制后可减少肝脏脂肪合成，增强胰岛素敏感性。动物实验显示，LX9851 单药或与 GLP-1 联用可防止体重反弹，解决现有疗法停药后复胖的痛点。安全性优势：无 GLP-1 相关胃肠道副作用（如恶心、腹泻），更适合长期使用。可能成为合并肝病患者的首选，因改善肝脂肪变性的潜力已获验证。四、行业影响：代谢疾病治疗的 “靶点轮动”投资风向转变：非 GLP-1 靶点（如 GIP、GCGR、ACSL5）融资额 2024 年同比增长 60%，默沙东、辉瑞等巨头加速布局。诺和此次交易为 2025 年最大代谢疾病并购案，带动 Lexicon 股价当日飙升 35%。市场格局重构：若 LX9851 成功，诺和将形成 “GLP-1（短期）+ACSL5（中期）+ 基因疗法（长期）” 的三代产品线。分析师预测，2030 年全球肥胖治疗市场将突破 2000 亿美元，多靶点组合或助诺和维持 40% 市场份额。五、挑战与风险临床转化风险：动物实验结果能否复制到人体尚未知，I 期需验证安全性和药代动力学。此前诺和 CagriSema（GLP-1 + 胰淀素）III 期数据不及预期，市场对非 GLP-1 药物存在疑虑。商业化竞争：礼来的 RET 抑制剂（如 LY3437943）、辉瑞的 GIP/GCGR 双靶点药物已进入 III 期，可能早于 LX9851 上市。六、专家观点：诺和的 “赌局” 与 “底气”积极派：Jefferies 分析师认为，“诺和的管线深度与商业化能力是其最大优势，即使 LX9851 失败，也可通过并购快速弥补。”谨慎派：SVB Leerink 指出，“ACSL5 靶点缺乏临床验证，需警惕研发周期延长和适应症拓展风险。”七、结语当 GLP-1 的 “药王” 光环逐渐褪色，诺和诺德正以 10 亿美元的代价开启代谢疾病治疗的新篇章。这场豪赌不仅关乎企业的增长曲线，更将重塑肥胖治疗领域的技术路径。而 ACSL5，这个曾被忽视的代谢调控节点，或将成为诺和帝国的下一个 “黄金靶点”—— 答案，将在 2026 年的 I 期临床数据中揭晓。参考来源：https://www.biospace.com/business/novos-obesity-pipeline-keeps-evolving-with-up-to-1b-lexicon-deal识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

引进/卖出临床3期基因疗法并购

2025-03-25

·药时代

20亿美元出海交易达成，股价却暴跌12%？

创新药管线出海，股价却遭大跌，二级市场那么不讲道理？ 2025年3月24日，联邦制药宣布与诺和诺德达成出海协议。后者获得前者GLP-1/GIP/GCG（GGG）受体激动剂UBT251的大中华区外全球权益，前者获得2亿美元预付款、18亿美元里程碑金额，以及一定比例的销售分成。本应皆大欢喜，联邦制药股价却于次日下跌12%。利好变为利空，不少散户直呼“看不懂”、“炒短线变成了炒洋芋（穷了Orz）”。 “利多”变“利空” 不是“20亿美元交易”不够吸引人，而是联邦制药发布了2024年全年报。2024年，联邦制药全年营收约137.59亿元，同比增长0.1%。其中，中间体、原料药、制剂业务分别上升1.8%、下降0.5%及下降5.9%，分部溢利同比分别上升5.9%、下降9.8%及下降47.0%。中间体与原料药属于联邦制药的传统业务，构成了公司营收大头。而制剂业务的大幅下滑，主要与国家集采导致的价格下调有关。此外，2024年联邦制药的制剂产品研发费用同比增长了26.6%，达5.772亿元。近几年，联邦制药布局了近20项1类新药，自免、眼科、抗感染和内分泌等多个领域。其中，UBT251便是其创新标杆之一。简单而言，就是年报停滞抵消了GLP-1出海的想象空间。联邦制药是一个颇有年头的公司，1990年成立，2007年香港上市。与多数本土老牌药企类似，最初通过中间体、原料药起家，后续转型做起了制剂业务，包括人用抗生素类、胰岛素类、动保等板块。这家药企的特点就是基本盘稳固，营收能力也较为稳健，特别是近年来随着胰岛素业务的增长（国内市场与甘李、通化东宝或为同在第一梯队）。2022年以来，联邦制药股价一直呈上升趋势，此次纵然有20亿美元交易铺垫，股价依旧大跌，可能是获利盘叠加年报停滞再叠加恐慌盘所致。图片来源：雪球值得一提的是，或许市场仍将联邦制药视为原料药企业，估值并不高，截止日前公司港股市值不过300亿元，尤其是对比港股上市药企与多数Biotech，联邦制药的盈利能力较为可观的情况下。早有“定数”的出海交易此次交易，早有定数。虽然现在下定论，像是“马后炮”。当诺和诺德下一代CagriSema（司美格鲁肽+Amylin类似物cagrilintide的复方制剂）三期数据读出时，这笔交易便有了达成的前提条件。药时代在《36周减重22%！又一重磅GLP-1产品公布临床结果，2025年还有哪些减重产品值得期待？》一文中提到，诺和诺德面对礼来替尔泊肽施压，可用的底牌中高剂量Wegovy”与“CagriSema”双双市场未达预期，外加司美格鲁肽被纳入美国Medicare新一轮价格谈判，诺和诺德需要“找补”，需要继续卷。此外，礼来手中除了已上市的替尔泊肽，GGG三重激动剂Retatrutide对诺和诺德的“威胁”最大，该药物是替尔泊肽的迭代产品，疗效或更优，48周减重幅度达24.2%。据不完全统计，全球布局GGG三重激动剂的药企并不多，目前进入临床在研共5款。图片来源：创药网礼来的Retatrutide已在全球开展9项三期临床；韩美的HM15211/efocipegtrutide在MASH的二期临床，HM15275单药在一期临床；民为生物的MWN109也在临床一期；然后就是联邦制药的UBT251，已完成一期研究并与近期开展了II期研究（减重与降糖）。其中，韩美GLP-1类药物的技术路径存在风险。此前，韩美与礼来、勃林格殷格翰、赛诺菲、强生的多项合作均以失败告终。鉴于此，2020年默沙东引进韩美GLP-1/GCG双靶点激动剂HM12525A的权益，预付款仅1000万美元，且主攻非酒精性脂肪性肝炎（NASH）领域。然后，UBT251脱颖而出。一是临床数据不错，早期DIO小鼠模型研究显示，UBT251的总体减重效果不亚于礼来的Retatrutide；1a期数据显示，1.0~4.5mg剂量范围内，受试者体重较基线明显下降，最大降低幅度（Emax）平均值范围为-3.19~-4.80kg，明显优于安慰剂组；1b期数据显示，在最高剂量组中（1mg/3mg/6mg），完成试验的受试者平均体重较基线下降15.1%，而安慰剂组受试者的平均体重较基线增加1.5%。图片来源：华创证券医药团队（2024-12-21）二是联邦制药估值偏低，其创新管线估值或许存在较大的“压价”空间。最后，就是UBT251中美两地临床可以同步开展。目前，UBT251已在中国获批开展针对成人2型糖尿病、超重或肥胖、代谢相关脂肪性肝病（MAFLD）和慢性肾脏病（CKD）的临床试验，并在美国获批开展针对成人2型糖尿病、超重或肥胖以及慢性肾脏病（CKD）的临床试验。所以说，这笔交易早有定数。当初，礼来用替尔泊肽头对头司美格鲁肽；现在，诺和诺德选择用UBT251对标Retatrutide，直接“硬刚”。小结： GLP-1无疑是划时代的靶点，其代谢领域地位，等同于肿瘤领域的PD-1，因此该靶点内卷严重。在一众MNC中，礼来、诺和诺德呈双寡头格局半分天下；罗氏、安进尝试再卷一卷多靶点；默沙东另辟蹊径，寻找其他差异化适应症；阿斯利康选择与CVRM（心血管、肾脏及代谢）业务线的其他管线做联合用药…… 大家都在“卷”，但各有各的卷法。而MNC的一举一动，无疑将对国内药企产生巨大影响，无论是竞品公司的商业活动，亦或是看似不相关的临床数据读出。参考资料： 1.联邦制药官网 2.雪球 3.【迷雾01】联邦制药 3933——Novo Nordisk大跌的最大受益者？（TruTheMist） 4.一图看清GLP-1RA减重数据20241221（华创新药） 5.GLP-1/GCG/GIP三重受体激动剂研究进展（创药网） 6.其他公开资料图片来源：pixabay 481款！2024年FDA孤儿药认证大爆发！中国排名第二 2025-03-24 阿斯利康2025中国宏图：不止和铂，还有...... 2025-03-22 股价暴跌41%！Elevation终止石药ADC的海外开发 2025-03-21 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击这里，查看更多精彩!

财报临床3期医药出海引进/卖出

2025-03-24

·BioPharmaDive

Novo adds to obesity drug pipeline via $200M deal with China-based biotech

Dive Brief:Novo Nordisk is expanding its pipeline of obesity medicines, announcing Monday it will pay China-based United Laboratories International Holdings $200 million upfront to license an experimental triple agonist weight loss shot that could take on Eli Lillys retatrutide.Per deal terms, Novo will have commercialization rights to the drug outside of China and nearby marketing territories, and could owe up to an additional $1.8 billion based on achievement of certain milestones by the drug, called UBT251. Novo would also pay royalties on sales in its marketing territories.Novo had a big head start in obesity, getting the GLP-1 drug Wegovy to people with obesity five years ahead of Eli Lilly and its medicine Zepbound. But Lilly is catching up quickly, showing in testing that Zepbound helps people lose more weight than Wegovy and closing the sales gap, which stands at $4.9 billion in 2024 to Wegovys $8.4 billion.Dive Insight:Both Novo and Lilly struggled to meet demand for their obesity drugs, forcing them to spend billions of dollars to boost their manufacturing capacity. With that issue now largely resolved, Novo is turning its attention to the competitive landscape, where it is facing a stiff challenge from Lilly and other potential rivals like Amgen, Pfizer, Zealand and Viking Therapeutics.Novo pioneered the use of drugs stimulating a gut hormone called GLP-1 to help people with obesity lose weight. Lilly showed that, by acting on a second one called GIP, Zepbound could improve GLP-1s efficacy. Now drugmakers are experimenting with the use of other related pathways called glucagon and amylin although Novos initial effort in that area, combining GLP-1 and amylin, has underperformed expectations.Lilly is leading in triple-acting drugs, too, with an experimental shot it calls retatrutide that could have Phase 3 results next year. Novo advanced a tri-agonist into Phase 1 trials last year, but with the deal announced today it would have a drug that has already completed a Phase 1 dosing trialThe addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases, said Martin Holst Lange, Novos executive vice president for development, in a statement.Novo said Uniteds medicine had a similar side effect profile as Wegovy, Zepbound and drugs in the class, and helped people who completed the trial lose 15.1% of their body weight over 12 weeks, compared with a 1.5% increase for people who got placebo.The new tri-agonist will join an already beefy pipeline, which includes the GLP-1/amylin drug CagriSema, for which Novo still has high hopes, a version of its GLP-1 diabetes pill Rybelsus in obesity and various combinations of GLP-1, GIP and amylin. '

临床1期引进/卖出临床2期

100 项与 CagriSema 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床3期	美国	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	日本	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	奥地利	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	加拿大	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	德国	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	匈牙利	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	印度	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	爱尔兰	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	马来西亚	Novo Nordisk A/S	2023-02-01
2型糖尿病	临床3期	波兰	Novo Nordisk A/S	2023-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05394519 (REDEFINE 2, NEWS 1 \| NEWS 2) 人工标引	临床3期	超重 \| 肥胖	-	CagriSema	夢醖膚襯窪壓顧築醖襯(壓簾壓廠糧網夢鬱衊願) = 夢範獵齋蓋簾齋觸築鏇窪醖淵獵廠積衊鏇醖鹽 (鬱憲觸選遞觸觸遞夢顧 ) 更多	不佳	2025-03-10
				Placebo	夢醖膚襯窪壓顧築醖襯(壓簾壓廠糧網夢鬱衊願) = 齋淵簾遞窪襯遞醖憲廠窪醖淵獵廠積衊鏇醖鹽 (鬱憲觸選遞觸觸遞夢顧 ) 更多
EASD2023	N/A	-	-	CagriSema	衊願廠糧觸醖衊網蓋選(餘壓網艱獵製壓鏇糧觸) = 窪鬱製醖艱膚積窪醖遞衊獵積鏇構積獵選製鹽 (餘製遞衊蓋憲築淵蓋夢 ) 更多	积极	2023-10-03
				Cagrisema (Weight matched group (WM))	衊願廠糧觸醖衊網蓋選(餘壓網艱獵製壓鏇糧觸) = 齋範網範壓構壓夢積襯衊獵積鏇構積獵選製鹽 (餘製遞衊蓋憲築淵蓋夢 )
NAASO2022	N/A	-	-	Vehicle control	壓窪範築獵齋夢願壓鑰(淵簾壓齋膚遞鏇構構憲) = 選夢蓋壓鹹範積遞積簾醖鬱憲範遞糧遞糧艱廠 (憲鑰齋遞遞製製衊襯廠 ) 更多	-	2022-11-21
				CagriSema	壓窪範築獵齋夢願壓鑰(淵簾壓齋膚遞鏇構構憲) = 觸願淵醖願繭蓋夢願壓醖鬱憲範遞糧遞糧艱廠 (憲鑰齋遞遞製製衊襯廠 ) 更多